title: Toxicity comparison of neoadjuvant versus adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in radical cystectomy patients.
abstract: A reduction in the toxicity of M-VAC chemotherapy has been postulated for patients who receive these drugs prior to radical cystectomy for muscle invasive bladder carcinoma. A review of the toxicity and patient dropout rates from a group of 9 patients who received neoadjuvant M-VAC was little different from 9 patients who were treated with M-VAC after radical cystectomy. This similarity suggests that preoperative M-VAC should not be favored on the basis of reduced patient morbidity.
authors.affiliation: Division of Urologic Surgery, University of Pittsburgh School of Medicine, Pennsylvania.
authors.forename: R R
authors.initials: RR
authors.lastname: Bahnson
authors.forename: M S
authors.initials: MS
authors.lastname: Ernstoff
authors.forename: R J
authors.initials: RJ
authors.lastname: Miller
authors.forename: W F
authors.initials: WF
authors.lastname: O'Donnell
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D003131:Combined Modality Therapy; D015653:Cystectomy; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014747:Vinblastine / Q000009:adverse effects
chemical_list: D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate